Summary

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country’s advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy’s growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Surgery
• Radiation Therapy
• Chemotherapy
o Temozolomide
o Lomustine
o Carmustine Wafers
o Other
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics / Outpatient Centers
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Norway
o Denmark
• Asia Pacific
o China
o Japan
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2033
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
4.4. Surgery
4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.5. Radiation Therapy
4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.6. Chemotherapy
4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.6.2. Temozolomide
4.6.2.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.6.3. Lomustine
4.6.3.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.6.4. Carmustine Wafers
4.6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.6.5. Other
4.6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
4.7. Targeted Therapy (Bevacizumab)
4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Glioblastoma Multiforme Treatment Market: End-Use Business Analysis
5.1. End-Use Market Share, 2024 & 2033
5.2. End-Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
5.4. Hospitals
5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
5.5. Clinics / Outpatient Centers
5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
5.6. Ambulatory Surgical Centers
5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Glioblastoma Multiforme Treatment Market: Countries Estimates & Trend Analysis
6.1. Country Market Share Analysis, 2024 & 2033
6.2. Country Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.3.1. U.S.
6.3.1.1. Key Country Dynamics
6.3.1.2. Target Disease Prevalence
6.3.1.3. Regulatory Framework
6.3.1.4. Reimbursement Framework
6.3.1.5. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. Canada
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Framework
6.3.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Mexico
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Framework
6.3.3.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Europe
6.4.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. UK Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Framework
6.4.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Framework
6.4.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Framework
6.4.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Regulatory Framework
6.4.8.4. Reimbursement Framework
6.4.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Target Disease Prevalence
6.4.9.3. Regulatory Framework
6.4.9.4. Reimbursement Framework
6.4.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. South Korea
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Thailand
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Latin America
6.6.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. Argentina
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Middle East and Africa
6.7.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.4. UAE
6.7.4.1. Key Country Dynamics
6.7.4.2. Target Disease Prevalence
6.7.4.3. Regulatory Framework
6.7.4.4. Reimbursement Framework
6.7.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Target Disease Prevalence
6.7.5.3. Regulatory Framework
6.7.5.4. Reimbursement Framework
6.7.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Merck & Co., Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Teva Pharmaceutical
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Sun Pharma
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Amneal Pharmaceuticals
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. F. Hoffmann-La Roche Ltd.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Amgen, Inc.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Pfizer Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Arbor Pharmaceuticals (Azurity)
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Karyopharm Therapeutics, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives

ページTOPに戻る

List of Tables/Graphs

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
Table 4. Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 5. Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 6. North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
Table 7. North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 8. North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 9. U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 10. U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 11. Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 12. Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 13. Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 14. Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 15. Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
Table 16. Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 17. Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 18. UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 19. UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 20. Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 21. Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 22. France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 23. France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 24. Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 25. Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 26. Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 27. Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 28. Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 29. Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 30. Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 31. Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 32. Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 33. Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 34. Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
Table 35. Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD
Table 36. Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 37. Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 38. Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 39. China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 40. China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 41. India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 42. India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 43. Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 44. Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 45. South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 46. South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 47. Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 48. Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 49. Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
Table 50. Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 51. Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 52. Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 53. Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 54. Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 55. Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 56. Middle East & Africa glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
Table 57. Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 58. Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 59. South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 60. South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 61. Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 62. Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 63. UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 64. UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
Table 65. Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
Table 66. Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)List of Figures

Fig. 1 Glioblastoma multiforme treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and end-use segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Pharmaceutical market value, 2024 (USD billion)
Fig. 12 Market trends & outlook
Fig. 13 Porter’s five force analysis
Fig. 14 PESTEL analysis
Fig. 15 Glioblastoma multiforme treatment market: By treatment: Key takeaways
Fig. 16 Glioblastoma multiforme treatment market, By treatment: market share, 2024 & 2033
Fig. 17 Surgery market, 2021 - 2033 (USD Million)
Fig. 18 Radiation therapy market, 2021 - 2033 (USD Million)
Fig. 19 Chemotherapy market, 2021 - 2033 (USD Million)
Fig. 20 Temozolomide market, 2021 - 2033 (USD Million)
Fig. 21 Lomustine settings market, 2021 - 2033 (USD Million)
Fig. 22 Carmustine wafers market, 2021 - 2033 (USD Million)
Fig. 23 Others market, 2021 - 2033 (USD Million)
Fig. 24 Targeted therapy market, 2021 - 2033 (USD Million)
Fig. 25 Tumor treating field (TTF) therapy market, 2021 - 2033 (USD Million)
Fig. 26 Glioblastoma multiforme treatment market: By End Use key takeaways
Fig. 27 Glioblastoma multiforme treatment market, By End Use: market share, 2024 & 2033
Fig. 28 Hospitals market, 2021 - 2033 (USD Million)
Fig. 29 Clinics / Outpatient Centers market, 2021 - 2033 (USD Million)
Fig. 30 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
Fig. 31 Others market, 2021 - 2033 (USD Million)
Fig. 32 Glioblastoma multiforme treatment market revenue, by region, 2024 & 2033 (USD Million)
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 U.S. Glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Key country dynamics
Fig. 39 Canada glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 Mexico glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Regulatory framework
Fig. 43 Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Japan glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 China glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Regulatory details: China
Fig. 49 Exclusivity formula
Fig. 50 Key country dynamics
Fig. 51 India glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Registration details: India
Fig. 53 Key country dynamics
Fig. 54 Australia glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 55 Contribution of PBS by disease
Fig. 56 Key country dynamics
Fig. 57 Thailand glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 South Korea glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 60 Reimbursement scenario
Fig. 61 Rest of Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 62 Argentina regulatory details
Fig. 63 Reimbursement scenario in Argentina
Fig. 64 Rest of Latin America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 65 MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 South Africa glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 68 Regulatory framework: South Africa
Fig. 69 Key country dynamics
Fig. 70 Saudi Arabia glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 71 Saudi Arabia pharmaceuticals regulation details
Fig. 72 Key country dynamics
Fig. 73 UAE glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Kuwait glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 76 Regulatory framework: Kuwait
Fig. 77 Rest of MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 78 Market participant categorization
Fig. 79 Strategic framework